Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.84 Million PLN | -43.46% |
| 2022 | 10.33 Million PLN | 31.96% |
| 2021 | 7.83 Million PLN | 54.02% |
| 2020 | 5.08 Million PLN | -31.28% |
| 2019 | 7.4 Million PLN | -16.03% |
| 2018 | 8.81 Million PLN | -1.4% |
| 2017 | 8.93 Million PLN | -22.31% |
| 2016 | 11.5 Million PLN | -8.85% |
| 2015 | 12.62 Million PLN | 25.38% |
| 2014 | 10.06 Million PLN | 0.36% |
| 2013 | 10.03 Million PLN | 59.41% |
| 2012 | 6.29 Million PLN | 81.42% |
| 2011 | 3.46 Million PLN | 29.66% |
| 2010 | 2.67 Million PLN | -38.68% |
| 2009 | 4.36 Million PLN | 85.94% |
| 2008 | 2.34 Million PLN | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -19 Thousand PLN | -100.33% |
| 2024 Q2 | 81 Thousand PLN | 652.63% |
| 2023 Q1 | 3.06 Million PLN | 6.8% |
| 2023 Q3 | -19 Thousand PLN | 99.37% |
| 2023 Q2 | -3.02 Million PLN | -198.86% |
| 2023 Q4 | 5.82 Million PLN | 30768.42% |
| 2023 FY | 5.84 Million PLN | -43.46% |
| 2022 Q3 | 2.77 Million PLN | 12.73% |
| 2022 Q2 | 2.45 Million PLN | 9.92% |
| 2022 Q4 | 2.86 Million PLN | 3.43% |
| 2022 FY | 10.33 Million PLN | 31.96% |
| 2022 Q1 | 2.23 Million PLN | 30.13% |
| 2021 Q2 | 1.89 Million PLN | -3.51% |
| 2021 FY | 7.83 Million PLN | 54.02% |
| 2021 Q4 | 1.71 Million PLN | -23.67% |
| 2021 Q3 | 2.25 Million PLN | 18.78% |
| 2021 Q1 | 1.96 Million PLN | 139.05% |
| 2020 Q1 | 1.79 Million PLN | 17.79% |
| 2020 Q2 | 749 Thousand PLN | -58.25% |
| 2020 Q4 | 822 Thousand PLN | -52.21% |
| 2020 FY | 5.08 Million PLN | -31.28% |
| 2020 Q3 | 1.72 Million PLN | 129.64% |
| 2019 Q2 | 1.28 Million PLN | -42.43% |
| 2019 Q4 | 1.52 Million PLN | -35.47% |
| 2019 FY | 7.4 Million PLN | -16.03% |
| 2019 Q1 | 2.23 Million PLN | 10.66% |
| 2019 Q3 | 2.36 Million PLN | 83.66% |
| 2018 Q3 | 2.12 Million PLN | 4.88% |
| 2018 Q4 | 2.01 Million PLN | -5.22% |
| 2018 FY | 8.81 Million PLN | -1.4% |
| 2018 Q2 | 2.02 Million PLN | -23.11% |
| 2018 Q1 | 2.63 Million PLN | 8.65% |
| 2017 FY | 8.93 Million PLN | -22.31% |
| 2017 Q2 | 2.55 Million PLN | 32.99% |
| 2017 Q1 | 1.92 Million PLN | -43.39% |
| 2017 Q3 | 2.03 Million PLN | -20.58% |
| 2017 Q4 | 2.42 Million PLN | 19.66% |
| 2016 Q3 | 3.31 Million PLN | 11.08% |
| 2016 FY | 11.5 Million PLN | -8.85% |
| 2016 Q4 | 3.39 Million PLN | 2.32% |
| 2016 Q2 | 2.98 Million PLN | 65.58% |
| 2016 Q1 | 1.8 Million PLN | -50.08% |
| 2015 Q1 | 2.9 Million PLN | -0.51% |
| 2015 Q3 | 3.3 Million PLN | 18.32% |
| 2015 Q4 | 3.61 Million PLN | 9.28% |
| 2015 FY | 12.62 Million PLN | 25.38% |
| 2015 Q2 | 2.79 Million PLN | -3.79% |
| 2014 Q4 | 2.92 Million PLN | 18.65% |
| 2014 Q2 | 1.85 Million PLN | -34.74% |
| 2014 Q1 | 2.83 Million PLN | 18.27% |
| 2014 FY | 10.06 Million PLN | 0.36% |
| 2014 Q3 | 2.46 Million PLN | 33.03% |
| 2013 Q2 | 2.7 Million PLN | 19.07% |
| 2013 Q4 | 2.39 Million PLN | -9.82% |
| 2013 FY | 10.03 Million PLN | 59.41% |
| 2013 Q1 | 2.27 Million PLN | 32.88% |
| 2013 Q3 | 2.65 Million PLN | -1.7% |
| 2012 FY | 6.29 Million PLN | 81.42% |
| 2012 Q3 | 1.85 Million PLN | 0.0% |
| 2012 Q4 | 1.7 Million PLN | -7.82% |
| 2011 FY | 3.46 Million PLN | 29.66% |
| 2010 FY | 2.67 Million PLN | -38.68% |
| 2009 FY | 4.36 Million PLN | 85.94% |
| 2008 FY | 2.34 Million PLN | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioceltix S.A. | -1.03 Million PLN | 662.868% |
| BIOTON S.A. | 72.85 Million PLN | 91.98% |
| Captor Therapeutics Spolka Akcyjna | 6.9 Million PLN | 15.331% |
| Mabion S.A. | 114.58 Million PLN | 94.901% |
| Molecure S.A. | -4.1 Million PLN | 242.456% |
| NanoGroup S.A. | -79.01 Thousand PLN | 7494.611% |
| Poltreg S.A. | -1.38 Million PLN | 521.269% |
| Pure Biologics Spólka Akcyjna | -2.57 Million PLN | 327.001% |
| Ryvu Therapeutics S.A. | 29.3 Million PLN | 80.062% |
| Synthaverse S.A. | 35.16 Million PLN | 83.385% |
| Urteste S.A. | -479 Thousand PLN | 1319.833% |